Anbogen Therapeutics, Inc., a Taipei, Taiwan-based clinical-stage firm creating most cancers therapies, raised USD 7.3M in Collection A+ funding.
The spherical was led by KGI Enterprise Capital and each new and present buyers.
The corporate intends to make use of the funds to help the Section II medical trial of ABT-301 together with PD-1 inhibitors for treating microsatellite secure (MSS) metastatic colorectal most cancers, which accounts for 95% of the metastatic colorectal most cancers inhabitants that doesn’t profit from immune checkpoint inhibitors.
Based by Dr. Joe Shih, Anbogen is a clinical-stage biotechnology firm devoted to creating precision anti-cancer medication and is dedicated to R&D improvements to enhance the lives of most cancers sufferers world wide. Two of its medication, ABT-101 for non-small cell lung most cancers (NSCLC) with HER2 exon20 insertion mutations and ABT-301(mix with immune checkpoint inhibitors) for metastatic colorectal most cancers, are at present in human medical trials.
FinSMEs
01/07/2024
